NovAliX Collaborates with Bruker to Innovate Drug Discovery
Thursday, 8 August 2024, 12:49
Introduction
French preclinical CRO NovAliX has found a new partner across the pond.
Strategic Investment
Massachusetts-based manufacturer Bruker Corporation has announced a minority investment in the CRO.
Benefits of Collaboration
- Advancing drug discovery techniques
- Leveraging Bruker's technologies
- Enhancing capabilities in preclinical stages
Conclusion
This partnership is set to transform the landscape of drug development, allowing NovAliX to strengthen its position in the industry and hasten the delivery of innovations.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.